Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ ...

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minuteAvailability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences Approval ...

Discover how quality control charts help track product standards, pinpoint issues, and ensure processes meet specifications with this essential tool for quality assurance.

Whew, what a game. I feel like I’ve written that coming out of several games this season, but I suppose that’s just the ...

President Trump’s trade policy, inflation and climbing stock prices shaped business and the economy this year.

Learn how the Least Squares Criterion determines the line of best fit for data analysis, enhancing predictive accuracy in finance, economics, and investing.

With Live Caption, Chrome generates captions in real time for almost any audio or video you’re playing. Just click the music ...

Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy December 17, ...

Discover the power of a burn up chart. See examples, learn how to create one, and track scope, progress, and team performance ...

Songmont also differentiated itself technically. While many Chinese bag makers relied on “split leather,” a composite of ...

Following this week's European Commission approval of Roche/Genentech's Gazyvaro (obinutuzumab) for the treatment of lupus nephritis (LN), Spherix Global Insights' latest RealTime Dynamix(TM): Lupus ...

Trefinti is a new systemic solution powered by TYMIRIUM technology for prevention and control of foliar and root-feeding ...